- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy in prostate cancer
Authors
Keywords
-
Journal
HISTOPATHOLOGY
Volume 60, Issue 1, Pages 216-231
Publisher
Wiley
Online
2011-12-24
DOI
10.1111/j.1365-2559.2011.04030.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib and other targeted therapies for renal cell carcinoma
- (2011) T Powles et al. BRITISH JOURNAL OF CANCER
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer
- (2011) Richard J. Lee et al. Clinical Genitourinary Cancer
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer
- (2010) J. Hofland et al. CANCER RESEARCH
- Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
- (2010) John Araujo et al. CANCER TREATMENT REVIEWS
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
- (2010) A. Zoubeidi et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis inhibitors in the treatment of prostate cancer
- (2010) Clara Hwang et al. Journal of Hematology & Oncology
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises
- (2010) Jeanny B. Aragon-Ching et al. Journal of Oncology
- VEGF Inhibitors and Prostate Cancer Therapy
- (2010) Jeanny Aragon-Ching et al. Current Molecular Pharmacology
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054
- (2009) James W. Growcott ANTI-CANCER DRUGS
- Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer
- (2009) K. Gravdal et al. CANCER RESEARCH
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- The utility of 5-α reductase inhibitors in the prevention and diagnosis of prostate cancer
- (2009) Amanda Beth Reed et al. CURRENT OPINION IN UROLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
- (2009) A. Craig Lockhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
- (2008) S. I. Park et al. CANCER RESEARCH
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
- (2008) K. N. Chi et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More